TCGA-D6-A74Q-01A-11R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.430
- OXIDATIVE_PHOSPHORYLATION+0.250
- DNA_REPAIR+0.200
- MYC_TARGETS_V1+0.150
- P53_PATHWAY+0.120
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.100
- APOPTOSIS+0.070
- BILE_ACID_METABOLISM+0.070
- TNFA_SIGNALING_VIA_NFKB+0.070
- ADIPOGENESIS+0.060
Top 10 suppressed
- PROTEIN_SECRETION-0.460
- UV_RESPONSE_DN-0.390
- ANDROGEN_RESPONSE-0.370
- CHOLESTEROL_HOMEOSTASIS-0.320
- MITOTIC_SPINDLE-0.310
- TGF_BETA_SIGNALING-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- IL6_JAK_STAT3_SIGNALING-0.270
- KRAS_SIGNALING_UP-0.250
- PI3K_AKT_MTOR_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A47W-01A-11R-A23W-07 | — | — | 0.818 |
| 2 | TCGA-XF-AAN1-01A-31R-A42T-07 | — | — | 0.810 |
| 3 | TCGA-E2-A576-01A-11R-A31O-07 | — | B | 0.793 |
| 4 | fa9f3cc6-06eb-4cfd-8f85-9d13df39d11e | — | — | 0.790 |
| 5 | SRR5088856 | — | — | 0.782 |
| 6 | TCGA-GU-A763-01A-11R-A32O-07 | — | — | 0.781 |
| 7 | TCGA-GD-A6C6-01A-21R-A31N-07 | — | — | 0.775 |
| 8 | TCGA-MT-A67A-01A-11R-A30B-07 | — | — | 0.773 |
| 9 | TCGA-PL-A8LY-01A-11R-A41B-07 | — | A | 0.767 |
| 10 | SRR9879286 | — | cohortSQ2 | 0.760 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |